Results 201 to 210 of about 25,082 (343)

Sacubitril/Valsartan attenuates progression of diabetic cardiomyopathy through immunomodulation properties: an opportunity to prevent progressive disease. [PDF]

Cardiovasc Diabetol
Karuna N, Kerrigan L, Edgar K, Ledwidge M, McDonald K, Grieve DJ, Watson CJ.   +6 more
europepmc   +1 more source

APP intracellular domain derived from amyloidogenic β- and γ-secretase cleavage regulates neprilysin expression [PDF]

, 2015
Marcus O.W. Grimm, Janine Mett, Christoph P. Stahlmann, Sven Grösgen, Viola J. Haupenthal, Tamara Blà ⁄ mel, Benjamin Hundsdörfer, Valerie C. Zimmer, Nadine Mylonas, Heikki Tanila, Ulrike Mà ⁄ ller, Heike S. Grimm, Tobias Hartmann   +12 more
openalex   +1 more source

Sacubitril/valsartan:beyond natriuretic peptides [PDF]

, 2017
Atlas, Bateman, Cannon, Carpentier, Cohn, Daniels, Dehlin, Dell’Italia, Emdin, Fan, Gainer, Graf, Hirata, Hubers, Ibebuogu, Kalra, Kon, Laine, Langenickel, Liang, Maack, McMurray, McMurray, McMurray, Meilandt, Miller, Mione, Mistry, Nagaya, Niederkofler, Ohno-Matsui, Okolicany, Packer, Parthasarathy, Pelc, Potter, Potter, Rechardt, Richards, Richards, Singh, Tom, Tsutamoto, Vardeny, Vodovar, Witherow, Wong, Yasojima, Zile   +48 more
core   +2 more sources

Finerenone, glycaemic status, and heart failure with mildly reduced or preserved ejection fraction: A prespecified analysis of the FINEARTS‐HF trial

European Journal of Heart Failure, EarlyView.
Finerenone and glycaemic status in patients with heart failure with mildly reduced/preserved ejection fraction. CI, confidence interval; CV, cardiovascular; HF, heart failure; HR, hazard ratio; RR, rate ratio. Abstract Aims The efficacy and safety of the non‐steroidal mineralocorticoid receptor antagonist, finerenone, have not been examined in patients
Jawad H. Butt, Pardeep S. Jhund, Alasdair D. Henderson, Brian L. Claggett, Akshay S. Desai, Carolyn S.P. Lam, Meike Brinker, Patrick Schloemer, Prabhakar Viswanathan, Andrea Lage, Katja Rohwedder, Michele Senni, Sanjiv J. Shah, Adriaan A. Voors, Faiez Zannad, Bertram Pitt, Muthiah Vaduganathan, Scott D. Solomon, John J.V. McMurray   +18 more
wiley   +1 more source

Microwave Irradiation Pre-Treatment as a Sustainable Method to Obtain Bioactive Hydrolysates from Chicken Feathers. [PDF]

Int J Mol Sci
Torices-Hernández Á, Gallego M, Mora L, Toldrá F.   +3 more
europepmc   +1 more source

Role of neprilysin inhibitor combinations in hypertension: insights from hypertension and heart failure trials [PDF]

, 2015
Chirag Bavishi, Franz H. Messerli, Bernard Kadosh, Luís M. Ruilope, Kazuomi Kario   +4 more
openalex   +1 more source

Minimization or withdrawal of oral pharmacotherapy in chronic heart failure patients with improved myocardial function: A systematic review

European Journal of Heart Failure, EarlyView.
This systematic review included seven studies that reported the outcomes of minimization or withdrawal of oral pharmacotherapy in chronic heart failure (HF) patients with improved myocardial function. There is a dearth of existing evidence, which supports only loop diuretic withdrawal and possibly carvedilol monotherapy.
Yuxiang Luo, Wenbin Xiao, Yusuf Z. Sener, Wouter C. Meijers, Robert M.A. van der Boon, Elfatih A. Hasabo, Osama Soliman, Rudolf A. de Boer, Kadir Caliskan   +8 more
wiley   +1 more source

Evaluation of the efficacy of angiotensin receptor-neprilysin inhibitor in patients with aortic stenosis undergoing transcatheter aortic valve implantation: protocol for a randomised, open-label, controlled study. [PDF]

BMJ Open
Kitahara H, Okita S, Sugawara T, Yaginuma H, Goto H, Yamamoto H, Kanda T, Matsuura K, Inaba Y, Hanaoka H, Matsumiya G, Kobayashi Y.   +11 more
europepmc   +1 more source

Correction: Corrigendum: N-terminal domain of Bothrops asper Myotoxin II Enhances the Activity of Endothelin Converting Enzyme-1 and Neprilysin [PDF]

, 2016
A. Ian Smith, Niwanthi W. Rajapakse, Oded Kleifeld, Bruno Lomonte, Nkumbu L. Sikanyika, Alexander James Spicer, Wayne C. Hodgson, Paul J. Conroy, David H. Small, David M. Kaye, Helena C. Parkington, James C. Whisstock, Sanjaya Kuruppu   +12 more
openalex   +1 more source

Ferric carboxymaltose assessment of morbidity and mortality in patients with iron deficiency and chronic heart failure (FAIR‐HF2‐DZHK05) trial: Baseline characteristics and comparison to other relevant clinical trials

European Journal of Heart Failure, EarlyView.
Differences in baseline characteristics between major trials of intravenous (IV) iron therapy in heart failure. LVEF, left ventricular ejection fraction; SGLT2, sodium–glucose cotransporter 2. Aims Prior randomized trials have reported conflicting evidence regarding the efficacy of intravenous (IV) iron in patients with heart failure with reduced ...
Stefan D. Anker, Tim Friede, Javed Butler, Khawaja M. Talha, Marius Placzek, Monika Diek, Anna Nosko, Adriane Stas, Stefan Kluge, Dominik Jarczak, Geraldine Deheer, Meike Rybczynski, Antoni Bayes‐Genis, Frank Edelmann, Gerasimos Filippatos, Gerd Hasenfuß, Wilhelm Haverkamp, Mitja Lainscak, Ulf Landmesser, Iain C. Macdougall, Bela Merkely, Burkert M. Pieske, Fausto J. Pinto, Tienush Rassaf, Maurizio Volterrani, Stephan von Haehling, Markus S. Anker, Wolfram Doehner, Hüseyin Ince, Friedrich Koehler, Gianluigi Savarese, Ursula Rauch‐Kröhnert, Tommaso Gori, Teresa Trenkwalder, Ibrahim Akin, Christina Paitazoglou, Iwona Kobielusz‐Gembala, Witold Zmuda, Luca Kuthi, Norbert Frey, Manuela Licka, Stefan Kääb, Karl‐Ludwig Laugwitz, Piotr Ponikowski, Mahir Karakas   +44 more
wiley   +1 more source